About Oncolytics Biotech
Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company have focused the research and development efforts on the development of REOLYSIN, the cancer therapeutic. The product for human use, REOLYSIN is developed from the reovirus. The virus has been demonstrated to replicate in the tumour cells bearing an activated Ras pathway. The Ras protein is a regulator of cell growth and differentiation. It transmits signals from the cell's surface, through growth factor receptors, to downstream elements, which are in turn relayed to the nucleus. The transmission of signals from the cell surface to the cell's nucleus is referred to as the signal transduction. The wholly owned subsidiaries of the Company include Oncolytics Biotech (Barbados) Inc. and Oncoltics Biotech (US) Inc. In April 2009, the Company completed the acquisition of an inactive private company.
|
|
|
11-50 employees
View all Oncolytics Biotech employees
|
|
IT Services and IT Consulting
|
|
403.670.7377
|
|
Calgary, Alberta
|
|
Unkn
|
Oncolytics Biotech Alternatives
Frequently Asked Questions about Oncolytics Biotech
The decision makers in Oncolytics Biotech are Allison Hagerman, Amy Levin, Deborah M Brown, etc. Click to Find Oncolytics Biotech decision makers emails.
Oncolytics Biotech Staff Directory
Search Oncolytics Biotech Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
